Does diabetes affect the survival of individuals with colorectal cancer?

Study reveals a link between complicated diabetes and a higher risk of death.

2023-10-23

(Press-News.org) Complications of diabetes can have numerous negative health effects, from impaired vision and nerve damage to kidney dysfunction and heart disease. In an analysis of information on adults with colorectal cancer, patients who also had diabetes—particularly those with diabetic complications—faced a higher risk of dying early. The results are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

For the study, Kuo‐Liong Chien, MD, PhD, of National Taiwan University, and his colleagues examined data registered between 2007 and 2015 in the Taiwan Cancer Registry Database, which is linked to health insurance and death records. Their analysis included 59,202 individuals with stage I–III colorectal cancer who underwent potentially curative surgery to remove their tumors. Among these patients, 9,448 experienced a cancer recurrence and 21,031 died from any cause during the study period.

Compared with individuals without diabetes, those with uncomplicated diabetes were at a minimally or insignificantly higher risk of all‐cause and cancer‐specific death, whereas those with complicated diabetes had 85% higher odds of death from any cause and 41% higher odds of death from cancer. These associations were more pronounced in women and in patients with early‐stage colorectal cancer.

Also, compared to patients without diabetes, patients with uncomplicated or complicated diabetes had a 10–11% higher risk of colorectal cancer recurrence.

The mechanisms behind the relationship between diabetic severity and poor colorectal cancer prognosis could involve various pathways and responses triggered by high insulin and glucose levels in the blood, as well as elevated inflammatory states, which are characteristic of type 2 diabetes.

“While a higher diabetes prevalence was noted in patients with colorectal cancer, the study suggests that coordinated medical care involving multiple specialists can help prevent diabetes complications, potentially improving long-term colorectal cancer oncological outcomes, particularly in women and patients with early-stage cancer,” said Dr. Chien.

Additional information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com

Full Citation:
“Diabetic severity and oncological outcomes of colorectal cancer following curative resection: A population‐based cohort study in Taiwan.” Hsin‐Yin Hsu, Yih‐Jong Chern, Min‐Shu Hsu, Tzu‐Lin Yeh, Ming‐Chieh Tsai, Jing‐Rong Jhuang, Lee‐Ching Hwang, Chun-Ju Chiang, Wen-Chung Lee, and Kuo-Liong Chien. CANCER; Published Online: October 23, 2023 (DOI: 10.1002/cncr.34975).

URL Upon Publication: http://doi.wiley.com/10.1002/cncr.34975

Author Contact: klchien@ntu.edu.tw

About the Journal    
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow CANCER on Twitter @JournalCancer and Instagram @ACSJournalCancer, and stay up to date with the American Cancer Society Journals on LinkedIn.

About Wiley
Wiley is a knowledge company and a global leader in research, publishing, and knowledge solutions. Dedicated to the creation and application of knowledge, Wiley serves the world’s researchers, learners, innovators, and leaders, helping them achieve their goals and solve the world's most important challenges. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.

END

ELSE PRESS RELEASES FROM THIS DATE:

Better regulation of mental health ‘therapies’ urgently needed to protect the vulnerable

2023-10-23

A rise in psychological pseudoscience is putting people at risk, psychologists have warned, with social media and celebrity endorsements partly to blame. Mental health apps, mood-boosting supplements and energy therapies are among the therapies that could do ‘more harm than good’ according to psychologists Jonathan Stea and Stephen Hupp in their new book Investigating Clinical Psychology. “As discourse around wellness, mental health, therapy, and access to these resources increasingly enter the public domain, the potential of coming across persuasive pseudoscience has also increased,” Stea explains. “This is the age of health misinformation. It is everywhere. ...

Do people everywhere care less about their cats than their dogs?

2023-10-23

Do canines get more care? Some studies have suggested pet owners are less emotionally attached to and less willing to finance care for cats than dogs, possibly because of cats’ behavior: cats may be perceived as caring less about humans and needing less care in return. But these studies are often conducted on non-representative samples and don’t consider possible cultural differences in attitudes to pets. A team of scientists led by Dr Peter Sandøe of the University of Copenhagen decided to investigate further. “We and others have found that people are willing to spend much less on their cats than ...

Association for Molecular Pathology appoints Lauren S. Menser as Chief Executive Officer

2023-10-23

ROCKVILLE, Md. – Oct. 23, 2023 – The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today announced the appointment of Lauren S. Menser, CAE, as its Chief Executive Officer, effective January 3, 2024. Menser will succeed Mary Steele Williams, MNA, MT(ASCP)SM, CAE, after her retirement. AMP’s national search for a new executive leader was administered by an outside consulting firm and overseen by a diverse group of member volunteers. Menser has served AMP in various capacities for more than 17 years. Since 2016, she has served as Director of Strategic Development, ...

Predictors of opioid overdose after prescription for chronic pain

2023-10-23

A large study published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.230459 identified 10 predictors of opioid overdose after prescription for chronic pain, which can help clinicians engage in shared decision-making with patients around opioid prescribing. “The opioid crisis has generated interest in identifying patients at higher risk of addiction or overdose and has led to the development of several screening tools; however, these instruments have either not been validated or shown poor psychometric properties,” writes Dr. Li Wang, a researcher and methodologist at the ...

Plant-based isn't just about burgers anymore

2023-10-23

A team of University of Waterloo researchers has created smart, advanced materials that will be the building blocks for a future generation of soft medical microrobots. These tiny robots have the potential to conduct medical procedures, such as biopsy, and cell and tissue transport, in a minimally invasive fashion. They can move through confined and flooded environments, like the human body, and deliver delicate and light cargo, such as cells or tissues, to a target position. The tiny soft robots are a maximum of one centimetre long and are bio-compatible and non-toxic. The robots are made of advanced hydrogel ...

Better use of existing drugs increases cervical cancer survival and reduces recurrence

2023-10-22

The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer. As part of an analysis of clinical data, the preliminary results will be presented at the European Society for Medical Oncology (ESMO) congress on Sunday 22 October 2023. The peak incidence of cervical cancer is in women in their early thirties, with around 3,200 new cases each year in the UK. CRT has been the standard treatment for cervical cancer since 1999, but despite improvements ...

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

2023-10-22

New York, NY (October 22, 2023) — A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer. The results were simultaneously reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology. The randomized phase 3 trial, named ”CheckMate 901,” showed significantly improved outcomes in patients who received the immunotherapy nivolumab with a combination of the chemotherapies gemcitabine and cisplatin, ...

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors, trial finds

2023-10-22

Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors Boston - A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators. Jennifer Chan, MD, MPH, director of the Program ...

Alliance presents detailed results from phase III CABINET pivotal Trial evaluating cabozantinib in advanced neuroendocrine tumors at ESMO 2023

2023-10-22

The Alliance for Clinical Trials in Oncology today announced detailed results will be presented at ESMO 2023 from CABINET (A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors (pNET) and a second cohort of patients with advanced extra-pancreatic NET (epNET). The study met the primary objective for each cohort, demonstrating that cabozantinib provided dramatic improvements in median progression-free survival (PFS) for the patients in the pNET and epNET cohorts. ...

ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer

2023-10-21

MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC). Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center. At a median follow-up of 25.4 months, the median EFS with chemotherapy alone was 18.4 months, while the median had not yet been reached for patients receiving perioperative nivolumab, meaning EFS was prolonged ...

Does diabetes affect the survival of individuals with colorectal cancer?

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: